Citeline Podcasts

By NorstellaBusiness

Citeline Podcasts episodes

May 12 The Scrip Awards Podcast - Call For Entries 2026, New AI Category, Triana Interview
25 min
May 12 Podcast: Inside Arcutis with CEO Frank Watanabe
Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation.
#biotech #dermatology #immunodermatology #pharma #drugdevelopment #leadershi
27 min
May 11 How Agentic AI Could Reshape Consumer Health, With IQVIA’s Volker Spitzer
In the latest episode of HBW Insight's Over the Counter podcast, Volker Spitzer, vice-president, global R&D/RWE services at IQVIA Consumer Health, returns to examine the implications of agentic AI for the consumer health industry – a topic he and colleagues explore in a recently published white paper.
Unlike the large language models now familiar to most consumers, agentic AI operates with persistent memory, cross-platform autonomy, and the ability to act on a user's behalf over time, functioning less like a search tool and more like a continuous personal health advisor.
In the first of this two-part conversation, we discuss important questions, such as: Can AI systems can yet be trusted to guide health decisions reliably? What is the role of the pharmacist in this evolution of health information technology? Is the existing product-focused regulatory framework equipped to govern a technology that operates as a dynamic, personalized recommendation engine rather than a fixed promotional claim?
Part two – published in two weeks’ time on HBW Insight – will address the commercial implications, including what the rise of agentic AI means for marketing strategy, industry readiness, and brand risk.
31 min
May 11 Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) May 11, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月8日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。
本期要闻: 诺和诺德抢占早期口服减肥药市场；葛兰素史克（GSK）交易强化其下游减肥药战略；辉瑞因Vyndamax和解协议前景转好；中国主导创纪录的新药上市；以及强生公司放弃两款淋巴瘤CAR-T疗法。
Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-IEFP6L4BNNCFTNMAXVIX54E6CQ/
19 min
May 11 Scrip's Five Must-Know Things - May 11, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended May 8, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.
This time – Novo winning early oral obesity market; GSK deal bolsters
downstream obesity strategy; brighter Pfizer outlook due to Vyndamax
settlements; China dominates record novel drug launches; and J&J drops two lymphoma CAR-Ts.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-IEFP6L4BNNCFTNMAXVIX54E6CQ/

18 min
May 08 Drug Fix: US FDA’s Makary Pressured To Resign, Continues Hiring, Reform Efforts
Pink Sheet Executive Editor Derrick Gingery, Senior
Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs consider the increasing pressure on US Food and Drug Administration Commissioner Martin Makary to resign and its long-term impact on the agency (:34). They also discuss Makary’s comments on patient anecdotes influencing regulatory decisions on psychedelic drugs and his new AI-enabled one-day facility inspection program (12:14), criticism of Makary’s Commissioner’s National Priority Voucher Program (18:49), and his intent to hire 3,000 new scientists (23:12).
#pharma #business
More On These Topics From The Pink Sheet
Psychedelic Testimonials Alone Cannot Meet Legal Approval Standard, US FDA’s Makary Says: https://insights.citeline.com/pink-sheet/pathways-and-standards/approval-standards/psychedelic-testimonials-alone-cannot-meet-legal-approval-standard-us-fdas-makary-says-OCRVXBPRMJAR3I5LCSA7QER724/
US FDA Piloting AI-Enabled One-Day Inspections To Expand Oversight, Improve Efficiency: https://insights.citeline.com/pink-sheet/compliance/manufacturing/us-fda-piloting-ai-enabled-one-day-inspections-to-expand-oversight-improve-efficiency-ULUXK3SYFVF4ZDHYTA4QWXNDJE/
US FDA Hiring 3,000 Scientists To Power Sweeping Reform Agenda, Makary Says: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-hiring-3000-scientists-to-power-sweeping-reform-agenda-makary-says-HCDJTHZFUFBSZL5C2DKCG7FPAE/
US FDA Limits Some Staff Performance Awards, In Part Because Funds Are Insufficient: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-limits-some-staff-performance-awards-in-part-because-funds-are-insufficient-YMV4DDERO5A5LO5AOSORPXWDGE/
34 min
May 08 Forum chief Gwyn Tudor puts the case for medtech development in Wales
BioWales Podcast: Getting Medtech Right In A Small Country
Maximizing The Tailwind From BioWales 2026
Gwyn Tudor, head of the MediWales forum, lays out the challenges, opportunities and funding on offer for healthtech founders who make Wales part of their strategic plan.
For healthtech companies looking to move from start-up to manufacturing and scale-up, Wales can be an attractive location, with its quality manufacturing facilities, expertise and often lower costs than in other parts of the UK.
That was one of the messages from Gwyn Tudor, chief executive of the Cardiff-based MediWales forum, “the independent life sciences network for Wales”, as he opened the BioWales in London 2026 conference and exhibition.
Interviewed by In Vivo for his take on the current commercial and innovation climate for healthtech companies considering operations in Wales, he said that adoption of new technologies by NHS Wales can be just as much of a challenge as in England.
He added that NHS Wales is an accessible partner and there is “always a conversation to be had in Wales about new technology and innovation.” Companies can access potential partners, supply chains and peer support through MediWales and events like MediWales Connects.
Tudor said: “Building relationships to reduce friction and move projects faster by helping people work together in a less transactional, more relationship-based approach is a clear characteristic of Wales.”
Its life sciences ecosystem of 288 companies, 12,000 employees and annual sales output of £2.5bn sales value from medtech, diagnostics, wound healing, regenerative medicine and cell therapy is relatively small on an international scale.
But it punches above its weight in medtech and diagnostics, Tudor told delegates at the bustling BioWales event, explaining in this In Vivo podcast his goal of “keeping all life sciences stakeholders in the room to come up with solutions.” That includes the healthcare provider, he said.
8 min
May 01 Drug Fix: The New Acting US FDA Biologics Center Director, SCOTUS Eyes Generic Drug Policy
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Generics Bulletin Executive Editor Dave Wallace discuss US Food and Drug Administration Commissioner Martin Makary’s appointment of Katherine Szarama as acting Center for Biologics Evaluation and Research director and the updated timeline for find a permanent director (:33), as well as and Makary’s approach compared to the recent Center for Drug Evaluation and Research leadership change (4:39). They also consider the impact of the US Supreme Court’s review of the generic drug skinny label policy (10:54).
#pharma #business
More On These Topics From The Pink Sheet
Alternate Leadership Strategy: Deputy Director Szarama Is
Acting US FDA Biologics Center Chief: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/alternate-leadership-strategy-deputy-director-szarama-is-acting-us-fda-biologics-center-chief-P6ZJLJY7YBDUXCG6DMWNYNIHUI/
US FDA’s Makary Expects To Name Permanent CBER Director
Within Weeks As Prasad Departs: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/fdas-makary-expects-to-name-permanent-cber-director-within-weeks-as-prasad-departs-37ZOLQT6FNDARGPMZOE2EI2DPE/
Skinny Label At SCOTUS: Could Generics Maintain
Carve-Out Authority No Matter The Decision?: ⁠https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/skinny-label-at-scotus-could-generics-maintain-carve-out-authority-no-matter-the-decision-54CTMA7XSBGIFF7WOYPGA26PGM/
26 min
May 01 Carna Health On Closing the Gap in CKD Prevention
Salvatore Viscomi, CEO and co-founder of Carna Health, discussed the company's pivotal work to combat the global crisis of chronic kidney disease (CKD).

26 min
April 30 What To Expect After China’s First siRNA Firm Went Public
In this episode of the China biopharma English-language podcast, Xu Hu talks about the siRNA area, including possible industry and R&D environment changes for Chinese firms developing these therapies and trends in deals of China-originated siRNA assets this year.
Story link: Chinese siRNA Contenders Set For Transitions, Deals In 2026
7 min

About Citeline Podcasts

From the publisher's feed

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and…